Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
The company also reported significant progress toward its internally defined Sustainable Development Goals
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
Subscribe To Our Newsletter & Stay Updated
